7 results on '"Groshkova, Teodora"'
Search Results
2. Effectiveness of methadone treatment for heroin addiction
- Author
-
Byford, Sarah, Barrett, Barbara, Metrebian, Nicola, Groshkova, Teodora, Cary, Maria, Charles, Vikki, Lintzeris, Nicholas, and Strang, John
- Published
- 2014
3. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction
- Author
-
Byford, Sarah, Barrett, Barbara, Metrebian, Nicola, Groshkova, Teodora, Cary, Maria, Charles, Vikki, Lintzeris, Nicholas, and Strang, John
- Published
- 2013
4. Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention
- Author
-
Wiessing, Lucas Ferri, Marica Grady, Bart Kantzanou, Maria and Sperle, Ida Cullen, Katelyn J. Hatzakis, Angelos Prins, Maria Vickerman, Peter Lazarus, Jeffrey V. Hope, Vivian D. and Mathei, Catharina Busch, Martin Bollaerts, Kaat and Bogdanova, Violeta Nesheva, Elmira Fotsiou, Nasia Kostrikis, Leontios Mravcik, Viktor Rehak, Vratislav Castkova, Jitka and Hobstova, Jirlina Nechanska, Blanka Fouchard, Jan and Abel-Ollo, Katri Tefanova, Valentina Tallo, Tatjana and Brummer-Korvenkontio, Henrikki Brisacier, Anne-Claire Michot, Isabelle Jauffret-Roustide, Marie Zimmermann, Ruth Fotiou, Anastasios Gazdag, Gabor Tarjan, Anna Galvin, Brian and Garavan, Carrie Thornton, Lelia Cruciani, Mario Basso, Monica Karnite, Anda Caplinskiene, Irma Lopes, Sofia and Origer, Alain Melillo, Jackie Camilleri, Moses Demanuele, Carlo Olivari Croes, Esther Op de Coul, Eline Rosinska, Magdalena Struzik, Marta Martins, Mario Duran, Domingos and Vilar, Graca Resende, Emilia Martins, Helena Cortes Abagiu, Adrian Octavian Ruta, Simona Arama, Victoria Kopilovic, Boris Kustec, Tanja Klavs, Irena Aleixandre, Noelia Llorens and Folch, Cinta Bravo, Maria Jose Gomez, Rosario Sendino and Berglund, Torsten Strandberg, Joakim Hope, Vivian Hotho, Daphne Van Houdt, Sabine Low, Andrea Mcdonald, Bethan and Platt, Lucy Isabelle Giraudon, Eleni Kalamara Groshkova, Teodora and Palladino, Claudia Hutchinson, Sharon Ncube, Fortune and Eramova, Irina Goldberg, David Vicente, Julian Griffiths, Paul EMCDDA DRID Grp
- Abstract
Background: People who inject drugs (PWID) are a key population affected by hepatitis C virus (HCV). Treatment options are improving and may enhance prevention; however access for PWID may be poor. The availability in the literature of information on seven main topic areas (incidence, chronicity, genotypes, HIV co-infection, diagnosis and treatment uptake, and burden of disease) to guide HCV treatment and prevention scale-up for PWID in the 27 countries of the European Union is systematically reviewed. Methods and Findings: We searched MEDLINE, EMBASE and Cochrane Library for publications between 1 January 2000 and 31 December 2012, with a search strategy of general keywords regarding viral hepatitis, substance abuse and geographic scope, as well as topic-specific keywords. Additional articles were found through structured email consultations with a large European expert network. Data availability was highly variable and important limitations existed in comparability and representativeness. Nine of 27 countries had data on HCV incidence among PWID, which was often high (2.7-66/100 person-years, median 13, Interquartile range (IQR) 8.7-28). Most common HCV genotypes were G1 and G3; however, G4 may be increasing, while the proportion of traditionally ‘difficult to treat’ genotypes (G1+G4) showed large variation (median 53,IQR 43-62). Twelve countries reported on HCV chronicity (median 72, IQR 64-81) and 22 on HIV prevalence in HCV-infected PWID (median 3.9%, IQR 0.2-28). Undiagnosed infection, assessed in five countries, was high (median 49%, IQR 38-64), while of those diagnosed, the proportion entering treatment was low (median 9.5%, IQR 3.5-15). Burden of disease, where assessed, was high and will rise in the next decade. Conclusion: Key data on HCV epidemiology, care and disease burden among PWID in Europe are sparse but suggest many undiagnosed infections and poor treatment uptake. Stronger efforts are needed to improve data availability to guide an increase in HCV treatment among PWID.
- Published
- 2014
5. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review
- Author
-
Mravcik, Viktor, Strada,Lisa, Å tolfa,Josef, Bencko,Bladimir, Groshkova,Teodora, Reimer,Jens, and Schulte,Bernd
- Subjects
Patient Preference and Adherence - Abstract
Viktor MravÄík,1,2 Lisa Strada,3 Josef Štolfa,4,5 Vladimir Bencko,6 Teodora Groshkova,7 Jens Reimer,3 Bernd Schulte3 1National Monitoring Centre for Drugs and Drug Addiction, 2Department of Addictology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 3Centre for Interdisciplinary Addiction Research, University of Hamburg, Hamburg, Germany; 4Department of General Practice, Institute for Postgraduate Medical Education in Prague, 5Department of General Practice, Second Faculty of Medicine, 6Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 7European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal Introduction and methods: Hepatitis C virus (HCV) infections are highly prevalent amongst people who inject drugs (PWID). Despite well documented evidence of its effectiveness, suggested cost-effectiveness, and potential to reduce HCV prevalence rates, the uptake of antiviral HCV treatment by PWID is low. This nonsystematic literature review describes factors associated with the uptake, adherence, and efficacy of HCV treatment among PWID and discusses strategies to increase their uptake of treatment. Results: Low HCV treatment uptake among PWID is associated with a number of patient-related and provider-related barriers. Beliefs and fears about low efficacy and adverse effects on the patient’s part are common. A substantial number of factors are associated with the chaotic lifestyle and altered social functioning of PWID, which are often associated with decompensation or relapsing into drug addiction. This may lead to perceived low adherence with treatment and low efficacy on the provider’s part too, where lack of support, inadequate management of addiction, and other drug-related problems and poor treatment of side effects have been described. Practical issues such as the accessibility of treatment and finances also play a role. Strategies to improve the HCV treatment rate among PWID involve pretreatment management and assessment, a multidisciplinary approach, management of side effects, and enhanced education and counseling. Conclusion: Specific factors are associated with poorer treatment outcomes in PWID on the side of both the patient and the treatment system. However, given that PWID can achieve treatment adherence and sustained virologic response rates comparable with those in nondrug users, drug use per se should not be considered a criterion for exclusion from treatment. Further development of measures leading to higher uptake of treatment and adherence in PWID and appropriate adaptation of HCV treatment guidelines represent important tools in this regard. Keywords: hepatitis C virus, people who inject drugs, treatment uptake, adherence, efficacy
- Published
- 2013
6. Authors' reply
- Author
-
Byford, Sarah, primary, Barrett, Barbara, additional, Metrebian, Nicola, additional, Groshkova, Teodora, additional, Cary, Maria, additional, Charles, Vikki, additional, Lintzeris, Nicholas, additional, and Strang, John, additional
- Published
- 2014
- Full Text
- View/download PDF
7. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review
- Author
-
MravÄÃk,Viktor, Strada,Lisa, Å tolfa,Josef, Bencko,Vladimir, Groshkova,Teodora, Reimer,Jens, Schulte,Bernd, MravÄÃk,Viktor, Strada,Lisa, Å tolfa,Josef, Bencko,Vladimir, Groshkova,Teodora, Reimer,Jens, and Schulte,Bernd
- Abstract
Viktor MravÄík,1,2 Lisa Strada,3 Josef Štolfa,4,5 Vladimir Bencko,6 Teodora Groshkova,7 Jens Reimer,3 Bernd Schulte3 1National Monitoring Centre for Drugs and Drug Addiction, 2Department of Addictology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 3Centre for Interdisciplinary Addiction Research, University of Hamburg, Hamburg, Germany; 4Department of General Practice, Institute for Postgraduate Medical Education in Prague, 5Department of General Practice, Second Faculty of Medicine, 6Institute of Hygiene and Epidemiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; 7European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal Introduction and methods: Hepatitis C virus (HCV) infections are highly prevalent amongst people who inject drugs (PWID). Despite well documented evidence of its effectiveness, suggested cost-effectiveness, and potential to reduce HCV prevalence rates, the uptake of antiviral HCV treatment by PWID is low. This nonsystematic literature review describes factors associated with the uptake, adherence, and efficacy of HCV treatment among PWID and discusses strategies to increase their uptake of treatment. Results: Low HCV treatment uptake among PWID is associated with a number of patient-related and provider-related barriers. Beliefs and fears about low efficacy and adverse effects on the patient’s part are common. A substantial number of factors are associated with the chaotic lifestyle and altered social functioning of PWID, which are often associated with decompensation or relapsing into drug addiction. This may lead to perceived low adherence with treatment and low efficacy on the provider’s part too, where lack of support, inadequate management of addiction, and other drug-related problems and poor treatment of side effects have been described. Practical issues such as the accessibility of treatment and finances also
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.